IL327043A - נוגדנים נגד tdp-43 ושימושיהם - Google Patents
נוגדנים נגד tdp-43 ושימושיהםInfo
- Publication number
- IL327043A IL327043A IL327043A IL32704326A IL327043A IL 327043 A IL327043 A IL 327043A IL 327043 A IL327043 A IL 327043A IL 32704326 A IL32704326 A IL 32704326A IL 327043 A IL327043 A IL 327043A
- Authority
- IL
- Israel
- Prior art keywords
- seq
- antibody
- variable domain
- chain variable
- occupied
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363538595P | 2023-09-15 | 2023-09-15 | |
| PCT/US2024/046651 WO2025059486A1 (en) | 2023-09-15 | 2024-09-13 | Anti-tdp-43 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL327043A true IL327043A (he) | 2026-05-01 |
Family
ID=92932943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL327043A IL327043A (he) | 2023-09-15 | 2024-09-13 | נוגדנים נגד tdp-43 ושימושיהם |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4777200A1 (he) |
| KR (1) | KR20260087722A (he) |
| CN (1) | CN122122178A (he) |
| AR (1) | AR133828A1 (he) |
| AU (1) | AU2024342582A1 (he) |
| IL (1) | IL327043A (he) |
| MX (1) | MX2026003216A (he) |
| TW (1) | TW202530253A (he) |
| WO (1) | WO2025059486A1 (he) |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| AU6014094A (en) | 1992-12-02 | 1994-06-22 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| MY128897A (en) | 1999-02-05 | 2007-02-28 | Samsung Electronics Co Ltd | Image texture retrieving method and apparatus thereof |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| EP1470146B8 (en) | 2001-12-28 | 2007-09-12 | Amgen Fremont Inc. | Antibodies against the muc18 antigen |
| DE50308030D1 (de) | 2002-11-29 | 2007-10-04 | Boehringer Ingelheim Pharma | Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| EP1820022B1 (en) | 2004-11-10 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | Use of flow-cytometric analysis to optimize cell banking strategies for cho cells |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| PL2099823T5 (pl) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
| EP2522730A1 (en) | 2007-03-02 | 2012-11-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of protein production |
| EP2189526B1 (en) * | 2007-07-06 | 2013-09-04 | Tokyo Metropolitan Institute of Medical Science | Antibody binding specifically to tdp-43 aggregate |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| CA2853412C (en) * | 2011-10-28 | 2021-05-04 | University Of Zurich | Tdp-43 specific binding molecules |
-
2024
- 2024-09-13 WO PCT/US2024/046651 patent/WO2025059486A1/en not_active Ceased
- 2024-09-13 IL IL327043A patent/IL327043A/he unknown
- 2024-09-13 TW TW113134924A patent/TW202530253A/zh unknown
- 2024-09-13 KR KR1020267010962A patent/KR20260087722A/ko active Pending
- 2024-09-13 AR ARP240102461A patent/AR133828A1/es unknown
- 2024-09-13 CN CN202480064333.2A patent/CN122122178A/zh active Pending
- 2024-09-13 EP EP24783060.7A patent/EP4777200A1/en active Pending
- 2024-09-13 AU AU2024342582A patent/AU2024342582A1/en active Pending
-
2026
- 2026-03-13 MX MX2026003216A patent/MX2026003216A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024342582A1 (en) | 2026-04-23 |
| CN122122178A (zh) | 2026-05-29 |
| TW202530253A (zh) | 2025-08-01 |
| MX2026003216A (es) | 2026-05-04 |
| AR133828A1 (es) | 2025-11-05 |
| KR20260087722A (ko) | 2026-06-11 |
| EP4777200A1 (en) | 2026-07-22 |
| WO2025059486A1 (en) | 2025-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL308808A (he) | נוגדנים נגד ccr8 ושימושים שלהם | |
| IL319931A (he) | נוגדנים אנטי- cd122 ושימושים בהם | |
| GB2610467B (en) | Anti-CLL1 antibody and application thereof | |
| GB202017058D0 (en) | Antibodies and uses thereof | |
| IL307267A (he) | נוגדני anti-cd122 ושימושיהם | |
| IL310662A (he) | נוגדנים אנטי- cd161ושימושים בהם | |
| IL307940A (he) | נוגדנים אנטי- adgre2ושימושים בהם | |
| IL327202A (he) | נוגדנים אנטי- cdh17 ושימושים בהם | |
| IL310810A (he) | נוגדנים אנטי- acvr2a ושימושים בהם | |
| IL308382A (he) | נוגדנים אנטי- cd276חדשים ושימושים בהם | |
| IL317391A (he) | נוגדנים חדשים אנטי- lilrb4ושימושים בהם | |
| EP4490199A4 (en) | MODIFIED ANTIBODIES AND THEIR USES | |
| IL320586A (he) | נוגדן נגד trem2 ושימושים שלו | |
| HRP20260098T1 (hr) | Anti-gprc5d monoklonska protutijela i njihova upotreba | |
| IL315438A (he) | נוגדנים אנטי-cd3 חדשים ושימושים בהם | |
| IL304412A (he) | נוגדנים כנגד cd112r ושימושים בהם | |
| IL307939A (he) | נוגדנים אנטי- clec12aושימושים בהם | |
| EP4464722A4 (en) | ANTIBODIES AND THEIR USE | |
| IL319145A (he) | נוגדנים חדשים אנטי- lilrb2ושימושים בהם | |
| IL316510A (he) | נוגדן אנטי-b7h3 ושימושיו | |
| IL312584A (he) | נוגדני anti-vista ושימושים בהם | |
| IL320972A (he) | נוגדנים אנטי-tfr1 ושימושים בהם | |
| IL317849A (he) | נוגדנים חד-שבטיים אנטי- slc34a2ושימושים בהם | |
| EP4437000A4 (en) | ANTI-TREM2 ANTIBODY AND ITS USES | |
| IL307233A (he) | נוגדנים אנטי- sema3aושימושים בהם |